Contagion Live: FDA accepts New Drug Application for zoliflodacin, oral antibiotic for uncomplicated gonorrhea
The US Food and Drug Administration (FDA) has accepted the New Drug Application for zoliflodacin, a novel, first-in-class oral antibiotic developed for the treatment of uncomplicated gonorrhea in adults and adolescents aged 12 years and older. The announcement was made jointly by Innoviva Specialty Therapeutics, Inc, and the Global Antibiotic Research & Development Partnership (GARDP).
Gonorrhea-causing bacteria have been gradually developing the ability to resist antibiotics; Researchers tested a new antibiotic called gepotidacin in people with uncomplicated gonorrhea; Gepotidacin, taken orally, was highly effective and generally well tolerated.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.